NASDAQ$EQ
Equillium Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Equillium's financial performance for Q2 2024 was reported, featuring revenue growth and a strengthened cash position.
Equillium reported a net income of $0.5 million for the second quarter of 2024, a significant improvement compared to the net loss of $3.3 million in the same period of 2023. Revenue increased to $13.9 million, driven by itolizumab development funding and amortization of the upfront payment. The company's cash balance increased to $33.3 million.
- Revenue for Q2 2024 was $13.9 million, up from $9.1 million in Q2 2023.
- Net income for Q2 2024 was $0.5 million, compared to a net loss of $3.3 million in Q2 2023.
- Cash, cash equivalents, and short-term investments totaled $33.3 million as of June 30, 2024.
- Ono Pharmaceutical has an option to acquire Equillium’s rights to itolizumab, with a decision expected by the end of October 2024.
Headline financials
Revenue & EPS history
Equillium · Revenue · Quarterly
$13.9M
Forward guidance
Equillium anticipates several milestones, including Ono's option exercise decision, EQ101's transition to subcutaneous delivery and Phase 2 dose optimization study, and EQ302's Phase 1 study initiation.
Tailwinds
- Potential for Ono to exercise its option to acquire Equillium’s rights to itolizumab, resulting in a $35.0 million payment.
- Advancement of EQ101 with transition to subcutaneous delivery and initiation of Phase 2 dose optimization study in alopecia areata.
- Advancement of EQ302 with plans to initiate Phase 1 clinical development in the second half of next year.
- Positive interim review of the Phase 3 EQUATOR study.
- Positive topline data from Phase 2 study of EQ101 in subjects with alopecia areata.
Headwinds
- Uncertainty regarding Ono’s decision to exercise its option.
- Potential delays in clinical trial timelines.
- Risks associated with transitioning EQ101 to subcutaneous delivery.
- Dependence on itolizumab development funding payments from Ono.
- Potential for increased research and development expenses.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2024
+1.0%
Avg return
Earnings day
-0.2%
Avg return
5 days after
-1.3%
Avg return
30 days after
55%
17 / 31 earnings
Positive
+42.0%
Q3 2020
Best reaction
-27.0%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +1.8% | -18.9% | — | |
| Q3 2025 | +23.8% | +20.2% | +52.4% | |
| Q2 2025 | +16.3% | +16.3% | +90.8% | |
| Q1 2025 | +5.4% | +5.4% | -5.4% | |
| Q1 2026 | +5.4% | +5.4% | -5.4% | |
| Q4 2024 | -2.5% | -10.0% | -16.0% | |
| Q3 2024 | -19.5% | -20.0% | -17.6% | |
| Q2 2024 | -4.6% | +0.0% | +27.4% | |
| Q1 2024 | -10.0% | -9.4% | -52.9% | |
| Q4 2023 | -27.0% | -18.1% | -36.5% | |
| Q3 2023 | -1.8% | +0.0% | +22.0% | |
| Q2 2023 | +3.9% | +2.6% | +6.5% | |
| Q1 2023 | +3.6% | +7.1% | +17.9% | |
| Q4 2022 | +12.3% | +10.8% | -4.6% | |
| Q3 2022 | +6.5% | +5.9% | -28.2% | |
| Q2 2022 | +1.4% | -1.8% | -25.5% | |
| Q1 2022 | +3.7% | +13.8% | +0.0% | |
| Q4 2021 | +0.0% | -9.1% | -10.3% | |
| Q3 2021 | -13.6% | -14.5% | -27.0% | |
| Q2 2021 | +2.7% | +2.2% | -2.4% | |
| Q1 2021 | +6.1% | +22.3% | +19.0% | |
| Q4 2020 | -8.5% | -12.7% | -19.5% | |
| Q3 2020 | +42.0% | +27.6% | +34.1% | |
| Q2 2020 | -12.8% | -29.7% | -45.0% | |
| Q1 2020 | -14.9% | -20.6% | -19.7% | |
| Q4 2019 | -1.1% | +2.3% | +7.5% | |
| Q3 2019 | -1.2% | +7.1% | +45.7% | |
| Q2 2019 | -0.5% | +7.1% | -0.5% | |
| Q1 2019 | +2.0% | +2.5% | +0.3% | |
| Q4 2018 | +6.1% | +9.2% | -20.2% | |
| Q3 2018 | +6.4% | -8.7% | -24.5% | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro